Table 3. Visit schedule.

Evaluation	Screening		Baseline		Follow-up
	V0		V1		V2 3 months	V3 6 months	V49 months	V512 months
Visit window	−3 to 1 d		−1 to 0 d		±7 d	±7 d	±7 d	±7 d
Informed consent	×
Demographic data	×
Medical histories	×
Symptoms	×				×	×	×	×
Vital signs			×		×	×	×	×
Physical examination			×		×	×	×	×
NYHA functional class	×				×	×	×	×
ECG			×					×
UCG			×					×
Blood routine			×		×	×	×	×
Coagulation function			×		×	×	×	×
Platelet function			×					×
Liver and kidney function			×		×	×	×	×
Myocardial enzyme			×		×	×	×	×
BNP/NT-proBNP			×					×
FBG			×					×
HBA1c			×					×
Lipid profile	×		×		×	×	×	×
Coronary angiography	×		×					×
OCT imaging	×		×					×
Endothelial function			×					×
SAQ			×		×	×	×	×
SF-36			×		×	×	×	×
PHQ-9			×		×	×	×	×
GAD-7			×		×	×	×	×
MMAS-8			×		×	×	×	×
Medications			×		×	×	×	×
MACE					×	×	×	×

X indicates that the procedure needs to be completed. NYHA, New York Heart Association; ECG, electrocardiogram; UCG, ultrasound cardiogram; BNP, B-type natriuretic peptide; NT-proBNP, N-terminal pro b-type natriuretic peptide; FBG, fasting blood glucose; HBA1c, hemoglobin A1c; OCT, optical coherence tomography; SAQ, Seattle Angina Pectoris Questionnaire; SF-36, Short-From-36 Health Survey; PHQ-9, Patient Health Questionnie-9; GAD-7, Generalized Anxiety Disorder Questionnie-7; MMAS-8, 8-item Morisky Medication Adherence Scale; MACE, major adverse cardiac event.